Full Text Journal Articles by
Author Fabien Zoulim

Advertisement

Find full text journal articles






Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital.

Victoria Ducray, Anna Sesilia Vlachomitrou, Maude Bouscambert-Duchamp, Salim Si-Mohamed, Sylvain Gouttard, Adeline Mansuy, Florian Wickert, Alain Sigal, Alexandre Gaymard, François Talbot, Catherine Michel, Thomas Perpoint, Jean-Baptiste Pialat, Olivier Rouviere, Laurent Milot, François Cotton, Philippe Douek, Muriel Rabilloud, Loic Boussel, ,

OBJECTIVES:To assess the diagnostic performances of chest CT for triage of patients in multiple emergency departments during COVID-19 epidemic, in comparison with reverse transcription polymerase chain reaction (RT-PCR) test. METHOD:From March 3 to April 4, 2020, 694 consecutive patients from three emergency departments of a large university hospital, for which ... Read more >>

Eur Radiol (European radiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.

Anais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, Fabien Zoulim, Albert Tran, Marc Bourlière, Paul Calès, Dominique Guyader, Jean-Pierre Bronowicki, Dominique Larrey, Christophe Hezode, Veronique Loustaud-Ratti, Jerome Gournay, Victor de Ledinghen, Tarik Asselah, Nathalie Ganne, Sophie Metivier, Olivier Chazouillères, Vincent Leroy, Isabelle Rosa, Didier Samuel, Philippe Mathurin, Carole Cagnot, Helene Fontaine, Fabrice Carrat, Stanislas Pol, ,

BACKGROUND:Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We performed a blind comparison of the kinetics of HCC recurrence in patients ... Read more >>

Clin Res Hepatol Gastroenterol (Clinics and research in hepatology and gastroenterology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.

Dominique Roulot, Ségolène Brichler, Richard Layese, Zahia BenAbdesselam, Fabien Zoulim, Vincent Thibault, Caroline Scholtes, Bruno Roche, Corinne Castelnau, Thierry Poynard, Olivier Chazouillères, Nathalie Ganne, Hélène Fontaine, Jerome Gournay, Dominique Guyader, Frédéric Le Gal, Pierre Nahon, Françoise Roudot-Thoraval, Emmanuel Gordien, ,

BACKGROUND & AIMS:HDV infection causes severe chronic liver disease in individuals infected with HBV. However, the factors associated with poor prognosis are largely unknown. Thus, we aimed to identify prognostic factors in patients with HDV infection. METHODS:The French National Reference Centre for HDV performed a nationwide retrospective study on 1,112 ... Read more >>

J. Hepatol. (Journal of hepatology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.

Etienne Audureau, Fabrice Carrat, Richard Layese, Carole Cagnot, Tarik Asselah, Dominique Guyader, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Ghassan Riachi, Paul Calès, Jean-Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean-Frédéric Blanc, Armand Abergel, Olivier Chazouillères, Ariane Mallat, Jean-Didier Grangé, Pierre Attali, Louis d'Alteroche, Claire Wartelle, Thông Dao, Dominique Thabut, Christophe Pilette, Christine Silvain, Christos Christidis, Eric Nguyen-Khac, Brigitte Bernard-Chabert, David Zucman, Vincent Di Martino, Angela Sutton, Stanislas Pol, Pierre Nahon, ,

BACKGROUND & AIMS:Refining hepatocellular carcinoma (HCC) surveillance programs requires improved individual risk prediction. Thus, we aimed to develop algorithms based on machine learning approaches to predict the risk of HCC more accurately in patients with HCV-related cirrhosis, according to their virological status. METHODS:Patients with compensated biopsy-proven HCV-related cirrhosis from the ... Read more >>

J. Hepatol. (Journal of hepatology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment.

Arthur Berger, Federico Ravaioli, Oana Farcau, Davide Festi, Horia Stefanescu, François Buisson, Pierre Nahon, Christophe Bureau, Nathalie Ganne-Carriè, Annalisa Berzigotti, Victor de Ledinghen, Salvatore Petta, Paul Calès, ,

BACKGROUND & AIMS:Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ... Read more >>

Clin. Gastroenterol. Hepatol. (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.

Victor de Lédinghen, Clovis Lusivika-Nzinga, Jean-Pierre Bronowicki, Fabien Zoulim, Dominique Larrey, Sophie Metivier, Albert Tran, Patrick Marcellin, Didier Samuel, Olivier Chazouillères, Stephane Chevaliez, Celine Dorival, Hélène Fontaine, Jean-Michel Pawlotsky, Fabrice Carrat, Stanislas Pol, ,

Sofosbuvir plus daclatasvir with or without ribavirin has demonstrated a high efficacy and an acceptable safety profile in clinical trials of patients infected with genotype 2 hepatitis Cvirus (HCV); however, there are currently no real-world data available for this regimen. To evaluate the real-life safety and efficacy of sofosbuvir/daclatasvir with ... Read more >>

J. Viral Hepat. (Journal of viral hepatitis)
[2020, 27(10):964-973]

Cited: 0 times

View full text PDF listing >>



Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!

Julie Lucifora, Maud Michelet, Michel Rivoire, Ulrike Protzer, David Durantel, Fabien Zoulim,

J. Hepatol. (Journal of hepatology)
[2020, 73(2):449-451]

Cited: 0 times

View full text PDF listing >>



Direct-acting antivirals and viral RNA targeting for hepatitis B cure.

Janine French, Stephen Locarnini, Fabien Zoulim,

PURPOSE OF REVIEW:The current aim in the HBV landscape is to develop therapeutic strategies to achieve a functional cure of infection, characterized by a sustained loss of HBsAg off-treatment. Current treatment options, that is, nucleos(t)ide analogues and IFN are effective at viral suppression but very poor at achieving HBsAg loss. ... Read more >>

Curr Opin HIV AIDS (Current opinion in HIV and AIDS)
[2020, 15(3):165-172]

Cited: 0 times

View full text PDF listing >>



Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.

Minseok Albert Kim, Seung Up Kim, Dong Hyun Sinn, Jeong Won Jang, Young-Suk Lim, Sang Hoon Ahn, Jae-Jun Shim, Yeon Seok Seo, Yang Hyun Baek, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Won Hyeok Choe, Hyung Joon Yim, Hyun Woong Lee, Jung Hyun Kwon, Sung Won Lee, Jae Young Jang, Hwi Young Kim, Yewan Park, Gi-Ae Kim, Hyun Yang, Han Ah Lee, Myeongseok Koh, Young-Sun Lee, Minkoo Kim, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim, Jeong-Hoon Lee,

OBJECTIVE:Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. ... Read more >>

Gut (Gut)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure.

Gregory C Fanning, Fabien Zoulim, Jinlin Hou, Antonio Bertoletti,

An amendment to this paper has been published and can be accessed via a link at the top of the paper. ... Read more >>

Nat Rev Drug Discov (Nature reviews. Drug discovery)
[2020, 19(4):291]

Cited: 0 times

View full text PDF listing >>



[Treatment of hepatitis C: decisive therapeutic advances].

Kerstin Hartig-Lavie, François Bailly, Fanny Lebossé, Marie Pagès-Ecochard, Fabien Zoulim,

Rev Prat (La Revue du praticien)
[2020, 70(2):e69-e70]

Cited: 0 times

View full text PDF listing >>



[Viral hepatitis].

Kerstin Hartig-Lavie, François Bailly, Fanny Lebossé, Marie Pagès-Ecochard, Fabien Zoulim,

Rev Prat (La Revue du praticien)
[2020, 70(2):e59-e68]

Cited: 0 times

View full text PDF listing >>



Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.

Matias A Avila, Jean-François Dufour, Alexander L Gerbes, Fabien Zoulim, Ramon Bataller, Patrizia Burra, Helena Cortez-Pinto, Bin Gao, Ian Gilmore, Philippe Mathurin, Christophe Moreno, Vladimir Poznyak, Bernd Schnabl, Gyongyi Szabo, Maja Thiele, Mark R Thursz,

Alcohol-related liver disease (ALD), which includes a range of disorders of different severity and is one of the most prevalent types of liver disease worldwide, has recently regained increased attention. Among other reasons, the realisation that any alcohol intake, regardless of type of beverage represents a health risk, and the ... Read more >>

Gut (Gut)
[2020, 69(4):764-780]

Cited: 0 times

View full text PDF listing >>



Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome, David Sheridan, Muhammad Y Sheikh, James Trotter, Whitfield Knapple, Eric Lawitz, Manal F Abdelmalek, Kris V Kowdley, Aldo J Montano-Loza, Jerome Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh MacConell, Reshma Shringarpure, Stephen Harrison, Arun J Sanyal, ,

BACKGROUND:Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic ... Read more >>

Lancet (Lancet (London, England))
[2019, 394(10215):2184-2196]

Cited: 13 times

View full text PDF listing >>



CD8+T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction.

Fanny Lebossé, Cathrin Gudd, Enes Tunc, Arjuna Singanayagam, Rooshi Nathwani, Evangelos Triantafyllou, Oltin Pop, Naveenta Kumar, Sujit Mukherjee, Tie Zheng Hou, Alberto Quaglia, Fabien Zoulim, Julia Wendon, Ameet Dhar, Mark Thursz, Charalambos G Antoniades, Wafa Khamri,

BACKGROUND:Cirrhosis-associated immune dysfunction (CAID) contributes to high sepsis risk in patients with chronic liver disease. Various innate and; to a lesser extent; adaptive immune dysfunctions have been described as contributors to CAID leading to immune-paresis and impaired anti-microbial response in cirrhosis. In this study, we examined the phenotype of CD8+T ... Read more >>

EBioMedicine (EBioMedicine)
[2019, 49:258-268]

Cited: 1 time

View full text PDF listing >>



Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡.

Markus Cornberg, Anna Suk-Fong Lok, Norah A Terrault, Fabien Zoulim, ,

Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic HBV treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilising cure is ... Read more >>

J. Hepatol. (Journal of hepatology)
[2020, 72(3):539-557]

Cited: 4 times

View full text PDF listing >>



Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.

Margarita Papatheodoridi, Emilia Hadziyannis, Françoise Berby, Kalliopi Zachou, Barbara Testoni, Eirini Rigopoulou, Nikolaos K Gatselis, Aggeliki Lyberopoulou, Ioannis Vlachogiannakos, Spilios Manolakopoulos, George N Dalekos, Fabien Zoulim, George V Papatheodoridis,

Reliable predictors of outcomes after treatment discontinuation in HBeAg-negative chronic hepatitis B (CHB) patients have not been established. We investigated the role of hepatitis B surface antigen (HBsAg), interferon-inducible protein-10 (IP10) and hepatitis B core-related antigen (HBcrAg) serum levels as predictors of HBsAg loss, relapse and retreatment in noncirrhotic HBeAg-negative ... Read more >>

J. Viral Hepat. (Journal of viral hepatitis)
[2020, 27(2):118-126]

Cited: 1 time

View full text PDF listing >>



Update of the statements on biology and clinical impact of occult hepatitis B virus infection.

Giovanni Raimondo, Stephen Locarnini, Teresa Pollicino, Massimo Levrero, Fabien Zoulim, Anna S Lok, ,

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight ... Read more >>

J. Hepatol. (Journal of hepatology)
[2019, 71(2):397-408]

Cited: 16 times

View full text PDF listing >>



Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.

Fanpu Ji, Yee Hui Yeo, Mike Tzuhen Wei, Eiichi Ogawa, Masaru Enomoto, Dong Hyun Lee, Etsuko Iio, John Lubel, Wenjun Wang, Bin Wei, Tatsuya Ide, Carmen Monica Preda, Fabio Conti, Tatsuya Minami, Rob Bielen, Hitomi Sezaki, Michele Barone, Philippe Kolly, Po-Sung Chu, Victor Virlogeux, Dennis Eurich, Linda Henry, Michelle B Bass, Takanori Kanai, Shuangsuo Dang, Zongfang Li, Jean-François Dufour, Fabien Zoulim, Pietro Andreone, Ramsey C Cheung, Yasuhito Tanaka, Norihiro Furusyo, Hidenori Toyoda, Akihiro Tamori, Mindie H Nguyen,

BACKGROUND & AIMS:The effect of hepatocellular carcinoma (HCC) on the response to interferon-free direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C (CHC) infection remains unclear. Using a systematic review and meta-analysis approach, we aimed to investigate the effect of DAA therapy on sustained virologic response (SVR) among patients ... Read more >>

J. Hepatol. (Journal of hepatology)
[2019, 71(3):473-485]

Cited: 5 times

View full text PDF listing >>



Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.

Anne Laurain, Sophie Metivier, Georges Haour, Dominique Larrey, Céline Dorival, Christophe Hezode, Fabien Zoulim, Patrick Marcellin, Marc Bourliere, Jean-Pierre Zarski, Dominique Thabut, Laurent Alric, Nathalie Ganne-Carrie, Paul Cales, Jean-Pierre Bronowicki, Ghassan Riachi, Claire Geist, Xavier Causse, Armand Abergel, Olivier Chazouilleres, Philippe Mathurin, Dominique Guyader, Didier Samuel, Albert Tran, Véronique Loustaud-Ratti, Ventzislava Petrov-Sanchez, Alpha Diallo, Clovis Luzivika-Nzinga, Hélène Fontaine, Fabrice Carrat, Stanislas Pol, ,

BACKGROUND:Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new oral antivirals from December 2013 to June 30, 2018. We report the results of sofosbuvir/simeprevir in ... Read more >>

BMC Infect. Dis. (BMC infectious diseases)
[2019, 19(1):300]

Cited: 1 time

View full text PDF listing >>



[Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue®) in the prevention of opioid overdoses].

Flavy Lenglard, Aurélie Berger-Vergiat, Delphine Ragonnet, Nathalie Duvernay, Philippe Lack, Emmanuel Poulet, Fabien Zoulim, Mathieu Chappuy,

OBJECTIVE:France has temporarily authorized addictology centers to use a form of intranasal naloxone (Nalscue®) to prevent opioid overdoses. The objectives of this work are to present both the characteristics of the patients included in this device in two hospitals centers and the results of the national survey on addiction center's ... Read more >>

Therapie (Therapie)
[2019, 74(4):477-486]

Cited: 0 times

View full text PDF listing >>



Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Fabrice Carrat, Hélène Fontaine, Céline Dorival, Mélanie Simony, Alpha Diallo, Christophe Hezode, Victor De Ledinghen, Dominique Larrey, Georges Haour, Jean-Pierre Bronowicki, Fabien Zoulim, Tarik Asselah, Patrick Marcellin, Dominique Thabut, Vincent Leroy, Albert Tran, François Habersetzer, Didier Samuel, Dominique Guyader, Olivier Chazouilleres, Philippe Mathurin, Sophie Metivier, Laurent Alric, Ghassan Riachi, Jérôme Gournay, Armand Abergel, Paul Cales, Nathalie Ganne, Véronique Loustaud-Ratti, Louis D'Alteroche, Xavier Causse, Claire Geist, Anne Minello, Isabelle Rosa, Moana Gelu-Simeon, Isabelle Portal, François Raffi, Marc Bourliere, Stanislas Pol, ,

BACKGROUND:Although direct-acting antivirals have been used extensively to treat patients with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well reported. We compared the incidence of death, hepatocellular carcinoma, and decompensated cirrhosis between patients treated with direct-acting antivirals and those untreated, in the French ANRS CO22 ... Read more >>

Lancet (Lancet (London, England))
[2019, 393(10179):1453-1464]

Cited: 27 times

View full text PDF listing >>



Hepatitis B.

Fabien Zoulim, Massimo Levrero, Barbara Testoni,

Nat Rev Gastroenterol Hepatol (Nature reviews. Gastroenterology & hepatology)
[2018, :]

Cited: 0 times

View full text PDF listing >>



Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis.

Jean-Philippe Bastard, Soraya Fellahi, Étienne Audureau, Richard Layese, Françoise Roudot-Thoraval, Carole Cagnot, Valérie Mahuas-Bourcier, Angela Sutton, Marianne Ziol, Jacqueline Capeau, Pierre Nahon, ,

An obesity-related altered adipose tissue secretion is suggested as a risk factor for hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) cirrhosis. However, no prospective study has yet examined the predictive value of circulating adipokines and immuno-inflammatory biomarkers regarding this risk. This was a case-control study nested in ... Read more >>

Eur. Cytokine Netw. (European cytokine network)
[2018, 29(3):112-120]

Cited: 0 times

View full text PDF listing >>



Very late relapse of hepatitis C virus infection immediately after liver transplant.

Domitille Erard-Poinsot, Caroline Scholtès, Claire Billoud, Fabien Zoulim, Jérôme Dumortier,

Late relapse of hepatitis C virus (HCV) infection is very rare in the era of modern direct-acting antiviral therapy. We report here the first case of a late relapse, after direct-acting antiviral therapy, occurring immediately after liver transplant (LT), with 93 weeks of sustained virologic response before LT. HCV RNA in ... Read more >>

Am. J. Transplant. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)
[2018, 18(10):2587-2590]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
2.3055 s